Daniel Scherman

This inventor holds 38 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 11 EPO patents, primarily in Nucleic Acid Delivery. Top assignees: Centre National De La Recherche Scientifique, National Institute of Health and Medical Research, Aventis Pharma S.a.. Active years: 1998-2022.

USPTO Granted Patents = 38 (Patent Applications = 3)

% Patents Active = 76.3

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 11 (Patent Applications = 13)

Average Co-Inventor Count = 4.0

ph-index = 10

Forward Citations = 417(Granted Patents)

Location History:

Paris Cedex, FR (2001)
Paris, FR (1998 - 2022)

Company Filing History:

12 out of 5,383

Centre National De La Recherche Scientifique

patents

11 out of 1,853

National Institute of Health and Medical Research

Rhone-Poulenc Rorer S.a.

patents

5. 7 out of 132

Université Paris Descartes

patents

6. 6 out of 331

Assistance Publique-Hopitaux De Paris

Université D'evry-Val-D'essonne

patents

11. 2 out of 11

Association Francaise Contre Les Myopathies

patents

12. 2 out of 13

Ecole Nationale Superieure De Chimie De Paris

patents

13. 2 out of 2

Enscp—chimie Paristech—ecole Nationale Superieure De Chimie De Paris

patents

14. 1 out of 1

Enscp—chimie Paris Tech—ecole National Superieure De Chimie De Paris

patent

15. 1 out of 1

Enscp—chimie Paris Tech—ecole Nationale Superieure De De Chime De Paris

patent

16. 1 out of 1

Enscp—chimie Paristech—ecole Nationale Superieure De Chime De Paris

patent

17. 1 out of 19

Institut De Recherche Pour Le Developpement (Ird)

patents

18. 1 out of 101

Institut Gustave Roussy

where one patent can have more than one assignee

Years Active: 1998-2022

Loading Chart...

Areas of Expertise:

Nucleic Acid Delivery

Optical Imaging

Cancer Treatment

Tumor Recurrence

Theranostics

Gene Transfer

Persistent Luminescence

Antibiotic-Free Cells

Transfection Agents

Muscle Mass

Vaccines

Ocular Therapeutics

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11492621 - Methods for the treatment of Leber congenital amaurosis (2022-11-08),

2. 11291630 - Gelling compositions for treating malignant tumours and/or preventing tumour recurrence (2022-04-05),

3. 10597654 - Methods for the treatment of Leber congenital amaurosis (2020-03-24),

4. 9877653 - Persistent luminescence nanoparticles excitable in situ for in vivo optical imaging, in vivo multimodal optical—MRI imaging, and theranostics (2018-01-30),

5. 9783547 - Water soluble 4-azapodophyllotoxin analogs (2017-10-10),

6. 9777272 - Methods for the treatment of Leber congenital amaurosis (2017-10-03),

7. 9572776 - Vectors including an anionic macromolecule and a cationic lipid for delivering small nucleic acids (2017-02-21),

8. 9540425 - Vaccines against pregnancy-associated malaria (2017-01-10),

9. 9487782 - Methods for the treatment of leber congenital amaurosis (2016-11-08),

10. 9474782 - Use of decorin for increasing muscle mass (2016-10-25),

11. 9175055 - Use of fibromodulin and lumican for increasing muscle mass (2015-11-03),

12. 9012425 - Methods for the treatment of Leber congenital amaurosis (2015-04-21),

13. 8709383 - Persistent luminescence nanoparticles used in the form of a diagnosis agent for in vivo optical imaging (2014-04-29),

14. 8440455 - Plasmic production and expression of recombinant proteins in cells grown without antibiotics (2013-05-14),

15. 8399636 - Purification of a triple helix formation with an immobilized obligonucleotide (2013-03-19),

Title: Daniel Scherman: A Visionary Inventor from Paris

Introduction:

Daniel Scherman, a distinguished inventor hailing from Paris, France, has left an indelible mark on the global inventor community with his groundbreaking innovations and unwavering commitment to scientific progress.

Latest Patents:

With an impressive portfolio of 37 patents, Daniel Scherman continues to push the boundaries of medical science. His recent patents include revolutionary methods for the treatment of Leber congenital amaurosis, a rare genetic eye disorder, and gelling compositions for the treatment of malignant tumors and prevention of tumor recurrence.

Career Highlights:

Throughout his illustrious career, Daniel Scherman has made significant contributions to the field of biotechnology and pharmaceuticals. Having worked at prestigious institutions such as the Centre National De La Recherche Scientifique and Aventis Pharma S.A., he has garnered a reputation for his innovative research and groundbreaking inventions.

Collaborations:

Daniel Scherman has collaborated with esteemed colleagues such as Pierre Wils and Antoine Kichler, who have played pivotal roles in the development and implementation of his groundbreaking inventions. Their collective efforts have led to advancements in medical science that have the potential to improve the lives of countless individuals around the world.

Conclusion:

In conclusion, Daniel Scherman stands as a beacon of innovation in the global inventor community. His relentless pursuit of excellence and unwavering dedication to scientific advancement continue to inspire future generations of inventors and researchers. Daniel Scherman's remarkable contributions to the field of biotechnology and pharmaceuticals have not only transformed medical science but have also paved the way for a brighter and healthier future for all.